Navigation Links
Multiple-drug resistant gene expression pattern predicts treatment outcome for pediatric leukemia

A new study is providing scientists with a better understanding of why some pediatric acute lymphoblastic leukemia (ALL) patients fail to respond to treatment even when existing clinical predictive criteria point towards a positive treatment outcome. The research, published in the April issue of Cancer Cell, is likely to facilitate development of new strategies to combat drug resistance and treatment failure for children with ALL.

Nearly 80% of children with ALL are cured following chemotherapeutic treatment. However, the remaining 20% often exhibit drug resistance and treatment failure that is poorly understood. In some cases, patients are resistant to multiple drugs that have very little structural similarity, suggesting that the mechanisms for drug cross-resistance are probably not the same as mechanisms underlying resistance to a single drug. Dr. William E. Evans from St. Jude Children's Research Hospital and colleagues used a comprehensive genetic screening technique to search for genes that are differentially expressed in ALL cells that demonstrated cross-resistance to two or more commonly used chemotherapeutic agents.

The researchers identified several genes that were differentially expressed in ALL cells that exhibited de novo cross resistance to four widely used antileukemic agents. They went on to investigate the relationship of these genes to treatment outcome in ALL patients and found that expression of the genes was associated with treatment outcome and could be used to identify a subset of patients with a markedly inferior response to treatment. In addition, the findings revealed a previously unrecognized phenotype characterized by discordant resistance to two widely used and mechanistically distinct antileukemic agents and provided new information about the cellular mechanisms involved in disparate response to these drugs.

Specific genetic signatures related to ALL treatment failure and chemotherapeutic cross-resistance were mor e effective at identifying select populations of patients with inferior treatment outcomes than expression patterns associated with resistance to a single drug. "These findings provide new insights into the biological basis of de novo multiple-drug resistance and illuminate potential new targets for overcoming this cause of treatment failure in childhood ALL," explains Dr. Evans.


'"/>

Source:Cell Press


Related biology news :

1. NYCs First Rapid HIV Drug-resistant AIDS Case Prompts Call to Step Up HIV Prevention
2. Drug-resistant bacteria on poultry products differ by brand
3. Genetic discovery could lead to drought-resistant plants
4. UF researchers kill resistant bugs one bandage at a time
5. DDT-resistant insects have additional genetic advantage that helps resistance spread
6. Drug resistant avian influenza viruses more common in Southeast Asia than North America
7. New molecule may aid in production of biofuels and fungi-resistant plants
8. Reducing antibiotic use lowers rates of drug-resistant bacteria
9. New class of antibiotics effective against drug-resistant bacteria discovered in fungi
10. Experimental TB drug effective against resistant and latent mycobacterium tuberculosis
11. Virginia Tech helping to develop higher quality, disease-resistant wheat varieties
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/16/2016)... , May 16, 2016   EyeLock LLC ... today announced the opening of an IoT Center of ... strengthen and expand the development of embedded iris biometric ... unprecedented level of convenience and security with unmatched biometric ... one,s identity aside from DNA. EyeLock,s platform uses video ...
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
(Date:4/28/2016)... FRANCISCO and BANGALORE, India , ... of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... provider, today announced a global partnership that will ... way to use mobile banking and payment services. ... is a key innovation area for financial services, but it ...
Breaking Biology News(10 mins):
(Date:6/23/2016)...   EpiBiome , a precision microbiome engineering company, ... financing from Silicon Valley Bank (SVB). The financing will ... its drug development efforts, as well as purchase additional ... has been an incredible strategic partner to us – ... would provide," said Dr. Aeron Tynes Hammack , ...
(Date:6/23/2016)... ... ... In a new case report published today in STEM CELLS Translational Medicine, doctors ... being treated for breast cancer benefitted from an injection of stem cells derived from ... frequent side effect of cancer treatment. , Lymphedema refers to the swelling ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... on quality, regulatory and technical consulting, provides a free webinar on ... on July 13, 2016 at 12pm CT at no charge. , Incomplete investigations ...
Breaking Biology Technology: